Symbols / CVRX Stock $5.22 -0.95% CVRx, Inc.
CVRX (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Ratings
Current target
$5.22
Low
$6.00
High
$14.00
Mean
$11.17
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-14 | main | Canaccord Genuity | Buy → Buy | $10 |
| 2026-02-13 | main | Canaccord Genuity | Buy → Buy | $10 |
| 2025-11-06 | main | Canaccord Genuity | Buy → Buy | $11 |
| 2025-11-06 | main | Cantor Fitzgerald | Overweight → Overweight | $13 |
| 2025-08-05 | reit | Cantor Fitzgerald | Overweight → Overweight | $11 |
| 2025-05-09 | main | Piper Sandler | Overweight → Overweight | $12 |
| 2025-05-09 | down | JP Morgan | Neutral → Underweight | $7 |
| 2025-04-08 | main | Lake Street | Buy → Buy | $14 |
| 2025-04-08 | main | Canaccord Genuity | Buy → Buy | $18 |
| 2025-02-05 | main | Piper Sandler | Overweight → Overweight | $20 |
| 2025-02-05 | main | Canaccord Genuity | Buy → Buy | $23 |
| 2025-01-17 | main | Craig-Hallum | Buy → Buy | $22 |
| 2025-01-14 | up | William Blair | Market Perform → Outperform | — |
| 2024-12-09 | main | Canaccord Genuity | Buy → Buy | $22 |
| 2024-11-04 | main | Craig-Hallum | Buy → Buy | $20 |
| 2024-10-30 | main | Lake Street | Buy → Buy | $15 |
| 2024-10-30 | main | Canaccord Genuity | Buy → Buy | $17 |
| 2024-10-30 | reit | Piper Sandler | Overweight → Overweight | $16 |
| 2024-10-23 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-09-10 | init | Cantor Fitzgerald | — → Overweight | $14 |
- CVRx heart device trial could expand Barostim patient pool threefold - Stock Titan Mon, 11 May 2026 20
- CVRX ($CVRX) Releases Q1 2026 Earnings - Quiver Quantitative Mon, 11 May 2026 20
- Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX) - Yahoo Finance Wed, 13 May 2026 13
- Earnings call transcript: CVRx beats Q1 2026 forecasts, stock rises - Investing.com Mon, 11 May 2026 21
- CVRX Inc (NASDAQ:CVRX) Q1 2026 Earnings Meet Revenue Estimates, Loss Slightly Narrower Than Expected - ChartMill Mon, 11 May 2026 21
- Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $14 - Moomoo Wed, 13 May 2026 22
- CVRx (CVRX) Q1 Loss Of US$13.1 Million Tests Bullish Revenue Growth Narrative - simplywall.st Wed, 13 May 2026 00
- Avoiding Lag: Real-Time Signals in (CVRX) Movement - Stock Traders Daily ue, 12 May 2026 11
- CVRx (CVRX) Q1 2026 Earnings Call Transcript - The Globe and Mail Mon, 11 May 2026 21
- CVRx (CVRX) reports Q1 loss, beats revenue estimates - MSN ue, 12 May 2026 18
- CVRx (NASDAQ: CVRX) grows Q1 2026 revenue 20% but remains loss-making - Stock Titan Mon, 11 May 2026 20
- $CVRX stock is up 9% today. Here's what we see in our data. - Quiver Quantitative Mon, 23 Feb 2026 08
- CVRx Q1 Earnings Call Highlights - The Globe and Mail Mon, 11 May 2026 23
- CVRx (NASDAQ: CVRX) grows Q1 revenue 20% as net loss narrows - Stock Titan ue, 12 May 2026 12
- CVRx Earnings Call Highlights Growth Amid Ongoing Losses - The Globe and Mail Wed, 13 May 2026 00
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
56.65
+10.45%
|
51.29
+30.53%
|
39.30
+74.89%
|
22.47
|
| Operating Revenue |
|
56.65
+10.45%
|
51.29
+30.53%
|
39.30
+74.89%
|
22.47
|
| Cost Of Revenue |
|
8.31
-0.28%
|
8.33
+33.22%
|
6.26
+25.15%
|
5.00
|
| Reconciled Cost Of Revenue |
|
8.31
-0.28%
|
8.33
+33.22%
|
6.26
+25.15%
|
5.00
|
| Gross Profit |
|
48.34
+12.53%
|
42.96
+30.02%
|
33.04
+89.12%
|
17.47
|
| Operating Expense |
|
99.61
-2.78%
|
102.45
+34.55%
|
76.14
+26.91%
|
60.00
|
| Research And Development |
|
11.13
+0.01%
|
11.13
-4.32%
|
11.63
+16.89%
|
9.95
|
| Selling General And Administration |
|
88.47
-3.11%
|
91.32
+41.56%
|
64.51
+28.90%
|
50.05
|
| Total Expenses |
|
107.92
-2.59%
|
110.78
+34.45%
|
82.40
+26.77%
|
65.00
|
| Operating Income |
|
-51.27
+13.83%
|
-59.49
-38.02%
|
-43.10
-1.35%
|
-42.53
|
| Total Operating Income As Reported |
|
-51.27
+13.83%
|
-59.49
-38.02%
|
-43.10
-1.35%
|
-42.53
|
| EBITDA |
|
-46.74
+14.85%
|
-54.89
-41.73%
|
-38.73
+4.94%
|
-40.74
|
| Normalized EBITDA |
|
-46.74
+14.85%
|
-54.89
-41.73%
|
-38.73
+4.94%
|
-40.74
|
| Reconciled Depreciation |
|
0.76
+22.13%
|
0.62
+18.58%
|
0.52
+26.70%
|
0.41
|
| EBIT |
|
-47.50
+14.44%
|
-55.51
-41.42%
|
-39.25
+4.62%
|
-41.15
|
| Net Income |
|
-53.31
+11.10%
|
-59.97
-45.55%
|
-41.20
+0.55%
|
-41.43
|
| Pretax Income |
|
-53.32
+10.99%
|
-59.91
-45.94%
|
-41.05
+0.65%
|
-41.32
|
| Net Non Operating Interest Income Expense |
|
-5.83
-32.52%
|
-4.40
-144.41%
|
-1.80
-990.30%
|
-0.17
|
| Interest Expense Non Operating |
|
5.83
+32.52%
|
4.40
+144.41%
|
1.80
+990.30%
|
0.17
|
| Net Interest Income |
|
-5.83
-32.52%
|
-4.40
-144.41%
|
-1.80
-990.30%
|
-0.17
|
| Interest Expense |
|
5.83
+32.52%
|
4.40
+144.41%
|
1.80
+990.30%
|
0.17
|
| Other Income Expense |
|
3.77
-5.26%
|
3.98
+3.30%
|
3.85
+180.41%
|
1.37
|
| Other Non Operating Income Expenses |
|
3.77
-5.26%
|
3.98
+3.30%
|
3.85
+180.41%
|
1.37
|
| Tax Provision |
|
-0.02
-132.73%
|
0.06
-62.59%
|
0.15
+34.86%
|
0.11
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-53.31
+11.10%
|
-59.97
-45.55%
|
-41.20
+0.55%
|
-41.43
|
| Net Income From Continuing Operation Net Minority Interest |
|
-53.31
+11.10%
|
-59.97
-45.55%
|
-41.20
+0.55%
|
-41.43
|
| Net Income From Continuing And Discontinued Operation |
|
-53.31
+11.10%
|
-59.97
-45.55%
|
-41.20
+0.55%
|
-41.43
|
| Net Income Continuous Operations |
|
-53.31
+11.10%
|
-59.97
-45.55%
|
-41.20
+0.55%
|
-41.43
|
| Normalized Income |
|
-53.31
+11.10%
|
-59.97
-45.55%
|
-41.20
+0.55%
|
-41.43
|
| Net Income Common Stockholders |
|
-53.31
+11.10%
|
-59.97
-45.55%
|
-41.20
+0.55%
|
-41.43
|
| Diluted EPS |
|
-2.04
+23.02%
|
-2.65
-33.17%
|
-1.99
+1.49%
|
-2.02
|
| Basic EPS |
|
-2.04
+23.02%
|
-2.65
-33.17%
|
-1.99
+1.49%
|
-2.02
|
| Basic Average Shares |
|
26.08
+15.44%
|
22.60
+8.87%
|
20.75
+1.08%
|
20.53
|
| Diluted Average Shares |
|
26.08
+15.44%
|
22.60
+8.87%
|
20.75
+1.08%
|
20.53
|
| Diluted NI Availto Com Stockholders |
|
-53.31
+11.10%
|
-59.97
-45.55%
|
-41.20
+0.55%
|
-41.43
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
115.23
|
| Current Assets |
|
112.09
|
| Cash Cash Equivalents And Short Term Investments |
|
90.57
|
| Cash And Cash Equivalents |
|
90.57
|
| Receivables |
|
7.55
|
| Accounts Receivable |
|
7.55
|
| Gross Accounts Receivable |
|
8.06
|
| Allowance For Doubtful Accounts Receivable |
|
-0.51
|
| Inventory |
|
10.98
|
| Raw Materials |
|
4.71
|
| Work In Process |
|
0.65
|
| Finished Goods |
|
5.62
|
| Prepaid Assets |
|
—
|
| Other Current Assets |
|
2.99
|
| Total Non Current Assets |
|
3.14
|
| Net PPE |
|
3.11
|
| Gross PPE |
|
5.90
|
| Accumulated Depreciation |
|
-2.79
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
1.18
|
| Construction In Progress |
|
0.55
|
| Other Properties |
|
4.07
|
| Leases |
|
0.10
|
| Other Non Current Assets |
|
0.03
|
| Total Liabilities Net Minority Interest |
|
39.28
|
| Current Liabilities |
|
7.86
|
| Payables And Accrued Expenses |
|
3.53
|
| Payables |
|
2.01
|
| Accounts Payable |
|
1.88
|
| Current Accrued Expenses |
|
1.52
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
4.11
|
| Total Tax Payable |
|
0.12
|
| Current Debt And Capital Lease Obligation |
|
0.23
|
| Current Capital Lease Obligation |
|
0.23
|
| Total Non Current Liabilities Net Minority Interest |
|
31.42
|
| Long Term Debt And Capital Lease Obligation |
|
30.38
|
| Long Term Debt |
|
29.22
|
| Long Term Capital Lease Obligation |
|
1.16
|
| Other Non Current Liabilities |
|
1.04
|
| Preferred Securities Outside Stock Equity |
|
—
|
| Stockholders Equity |
|
75.95
|
| Common Stock Equity |
|
75.95
|
| Capital Stock |
|
0.21
|
| Common Stock |
|
0.21
|
| Share Issued |
|
20.88
|
| Ordinary Shares Number |
|
20.88
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
553.33
|
| Retained Earnings |
|
-477.38
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.21
|
| Other Equity Adjustments |
|
-0.21
|
| Total Equity Gross Minority Interest |
|
75.95
|
| Total Capitalization |
|
105.17
|
| Working Capital |
|
104.23
|
| Invested Capital |
|
105.17
|
| Total Debt |
|
30.61
|
| Capital Lease Obligations |
|
1.39
|
| Net Tangible Assets |
|
75.95
|
| Tangible Book Value |
|
75.95
|
| Interest Payable |
|
0.22
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-40.17
-2.62%
|
-39.14
-0.32%
|
-39.02
+8.57%
|
-42.68
|
| Cash Flow From Continuing Operating Activities |
|
-40.17
-2.62%
|
-39.14
-0.32%
|
-39.02
+8.57%
|
-42.68
|
| Net Income From Continuing Operations |
|
-53.31
+11.10%
|
-59.97
-45.55%
|
-41.20
+0.55%
|
-41.43
|
| Depreciation Amortization Depletion |
|
0.76
+22.13%
|
0.62
+18.58%
|
0.52
+26.70%
|
0.41
|
| Depreciation |
|
0.76
+22.13%
|
0.62
+18.58%
|
0.52
+26.70%
|
0.41
|
| Depreciation And Amortization |
|
0.76
+22.13%
|
0.62
+18.58%
|
0.52
+26.70%
|
0.41
|
| Other Non Cash Items |
|
0.24
+18.72%
|
0.20
+31.82%
|
0.15
+516.00%
|
0.03
|
| Stock Based Compensation |
|
11.05
-41.98%
|
19.05
+202.24%
|
6.30
+62.16%
|
3.89
|
| Operating Gains Losses |
|
0.09
|
—
|
0.00
|
—
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
0.09
|
0.00
-100.00%
|
0.00
|
0.00
|
| Change In Working Capital |
|
1.00
+5.48%
|
0.95
+119.75%
|
-4.80
+13.78%
|
-5.57
|
| Change In Receivables |
|
-1.40
+18.64%
|
-1.72
+16.12%
|
-2.05
+30.47%
|
-2.94
|
| Changes In Account Receivables |
|
-1.40
+18.64%
|
-1.72
+16.12%
|
-2.05
+30.47%
|
-2.94
|
| Change In Inventory |
|
-0.10
+91.28%
|
-1.12
+72.08%
|
-4.03
-30.84%
|
-3.08
|
| Change In Prepaid Assets |
|
-0.54
-202.26%
|
0.53
-58.29%
|
1.27
+177.91%
|
-1.63
|
| Change In Payables And Accrued Expense |
|
3.04
-6.75%
|
3.26
+65280.00%
|
-0.01
-100.24%
|
2.08
|
| Change In Accrued Expense |
|
1.79
-30.18%
|
2.56
+1606.47%
|
-0.17
-119.47%
|
0.87
|
| Change In Payable |
|
1.25
+79.23%
|
0.70
+323.03%
|
0.17
-86.35%
|
1.21
|
| Change In Account Payable |
|
1.25
+79.23%
|
0.70
+323.03%
|
0.17
-86.35%
|
1.21
|
| Investing Cash Flow |
|
-0.58
+57.38%
|
-1.36
-130.29%
|
-0.59
+13.72%
|
-0.69
|
| Cash Flow From Continuing Investing Activities |
|
-0.58
+57.38%
|
-1.36
-130.29%
|
-0.59
+13.72%
|
-0.69
|
| Net PPE Purchase And Sale |
|
-0.58
+57.38%
|
-1.36
-130.29%
|
-0.59
+13.72%
|
-0.69
|
| Purchase Of PPE |
|
-0.58
+57.38%
|
-1.36
-130.29%
|
-0.59
+13.72%
|
-0.69
|
| Capital Expenditure |
|
-0.58
+57.38%
|
-1.36
-130.29%
|
-0.59
+13.72%
|
-0.69
|
| Financing Cash Flow |
|
10.52
-81.17%
|
55.87
+132.95%
|
23.98
+220.09%
|
7.49
|
| Cash Flow From Continuing Financing Activities |
|
10.52
-81.17%
|
55.87
+132.95%
|
23.98
+220.09%
|
7.49
|
| Net Issuance Payments Of Debt |
|
0.00
-100.00%
|
20.00
-11.11%
|
22.50
+200.00%
|
7.50
|
| Issuance Of Debt |
|
0.00
-100.00%
|
20.00
-11.11%
|
22.50
+200.00%
|
7.50
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
20.00
-11.11%
|
22.50
+200.00%
|
7.50
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
-100.00%
|
20.00
-11.11%
|
22.50
+200.00%
|
7.50
|
| Net Common Stock Issuance |
|
8.97
-72.41%
|
32.52
|
0.00
|
0.00
|
| Common Stock Payments |
|
—
|
—
|
—
|
0.00
|
| Repurchase Of Capital Stock |
|
—
|
—
|
—
|
0.00
|
| Proceeds From Stock Option Exercised |
|
1.55
-55.84%
|
3.50
+110.52%
|
1.66
+115.69%
|
0.77
|
| Net Other Financing Charges |
|
—
|
-0.15
+15.08%
|
-0.18
+76.99%
|
-0.78
|
| Changes In Cash |
|
-30.23
-296.75%
|
15.37
+198.32%
|
-15.63
+56.43%
|
-35.87
|
| Effect Of Exchange Rate Changes |
|
0.01
+600.00%
|
-0.00
-133.33%
|
0.00
+133.33%
|
-0.01
|
| Beginning Cash Position |
|
105.93
+16.96%
|
90.57
-14.71%
|
106.19
-25.25%
|
142.07
|
| End Cash Position |
|
75.71
-28.53%
|
105.93
+16.96%
|
90.57
-14.71%
|
106.19
|
| Free Cash Flow |
|
-40.75
-0.60%
|
-40.51
-2.25%
|
-39.61
+8.65%
|
-43.36
|
| Interest Paid Supplemental Data |
|
5.04
+39.60%
|
3.61
+158.88%
|
1.40
+2266.10%
|
0.06
|
| Income Tax Paid Supplemental Data |
|
—
|
0.00
-100.00%
|
0.00
-20.00%
|
0.01
|
| Common Stock Issuance |
|
8.97
-72.41%
|
32.52
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
8.97
-72.41%
|
32.52
|
0.00
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-05-12 View
- 8-K2026-05-11 View
- 8-K2026-04-13 View
- 42026-03-16 View
- 42026-03-04 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 8-K2026-03-03 View
- 42026-02-23 View
- 42026-02-18 View
- 10-K2026-02-13 View
- 8-K2026-02-12 View
- 8-K2026-01-12 View
- 8-K2026-01-12 View
- 42025-12-01 View
- 42025-11-25 View
- 42025-11-14 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|